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Abstract
Background: The relative efficacy and safety of proton pump inhibitors (PPIs) compared to histamine-2-receptor
antagonists (H2RAs) should guide their use in reducing bleeding risk in the critically ill.
Methods: We searched the Cochrane library, MEDLINE, EMBASE, ACPJC, clinical trials registries, and conference
proceedings through November 2015 without language or publication date restrictions. Only randomized
controlled trials (RCTs) of PPIs vs H2RAs for stress ulcer prophylaxis in critically ill adults for clinically important
bleeding, overt gastrointestinal (GI) bleeding, nosocomial pneumonia, mortality, ICU length of stay and Clostridium
difficile infection were included. We used the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach to assess our confidence in the evidence for each outcome.
Results: In 19 trials enrolling 2117 patients, PPIs were more effective than H2RAs in reducing the risk of clinically
important GI bleeding (RR 0.39; 95 % CI 0.21, 0.71; P = 0.002; I2 = 0 %, moderate confidence) and overt GI bleeding
(RR 0.48; 95 % CI 0.34, 0.66; P < 0.0001; I2 = 3 %, moderate confidence). PPI use did not significantly affect risk of
pneumonia (RR 1.12; 95 % CI 0.86, 1.46; P = 0.39; I2 = 2 %, low confidence), mortality (RR 1.05; 95 % CI 0.87,
1.27; P = 0.61; I2 = 0 %, moderate confidence), or ICU length of stay (mean difference (MD), –0.38 days; 95 % CI –1.49,
0.74; P = 0.51; I2 = 30 %, low confidence). No RCT reported Clostridium difficile infection.
Conclusions: PPIs were superior to H2RAs in preventing clinically important and overt GI bleeding, without
significantly increasing the risk of pneumonia or mortality. Their impact on Clostridium difficile infection is yet
to be determined.
Background
Over four decades ago, investigators first described
stress ulcer bleeding in critically ill patients [1]. Since
then, multiple studies have described this condition and
its impact on the prognosis of critically ill patients.
Stress ulcers typically occur in the gastric body, esopha-
gus, or duodenum, sometimes resulting in gastrointes-
tinal (GI) bleeding. Earlier studies reported overt GI
bleeding in 5 to 25 % of critically ill patients [2, 3]. In
contrast, the incidence of clinically important GI
bleeding is much lower, estimated between 1 and 4 %
[2, 4–7]. A recent large observational study (1034 pa-
tients, 97 sites), reported a 2.6 % incidence of clinic-
ally important GI bleeding [7], which was previously
found to be associated with increased intensive care
unit (ICU) mortality and length of stay [8]. Despite
reduction in clinically important GI bleeding, pharmaco-
logic stress ulcer prophylaxis does not seem to affect mor-
tality in randomized controlled trials (RCTs) [8].
RCTs have investigated different classes of medication
for stress ulcer prophylaxis. Recently, a meta-analysis of
29 RCTs showed that prophylaxis with either proton
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pump inhibitors (PPIs) or histamine-2-receptor antago-
nists (H2RAs) was associated with lower risk of overt GI
bleeding compared to placebo or no prophylaxis [9].
However, the relative effectiveness of the two classes of
agent remains uncertain.
PPIs, more potent at increasing gastric pH than
H2RAs and maintaining gastric pH between 3.5 and 5.0,
may minimize the risk of gastric mucosal injury [10]. Of
four meta-analyses comparing PPIs to H2RAs, three
suggested that PPIs are superior to H2RAs [11–13] and
one did not [14].
The Surviving Sepsis Campaign (SSC) guidelines rec-
ommend using stress ulcer prophylaxis among critically
ill patients with risk factors (e.g., mechanically ventilated
patients, and patients with coagulopathy), including a
weak recommendation for using PPIs over H2RAs in
this setting [15]. The advice is concordant with current
practice: recent observational studies showed that PPIs
are the most commonly used prophylactic agents in the
ICU [16–18].
In terms of the relative impact of PPIs and H2RAs,
adverse effects are also a concern. In particular, a re-
cent large retrospective observational study suggested
PPI versus H2RA use in critically ill patients was as-
sociated with higher risks of pneumonia and Clos-
tridium difficile infection compared to H2RA [19].
These results are, however, limited by the observa-
tional study design.
Several RCTs have been published recently and may
influence both risk of bias and precision [20–25]. There-
fore, we conducted a systematic review and meta-
analysis to evaluate the efficacy and safety of PPIs com-
pared to H2RAs for stress ulcer prophylaxis in critically
ill patients. We used the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology to assess the quality of evidence [26].
Methods
Study selection
Studies were eligible if: (1) the study design was an RCT;
(2) the population involved adult critically ill patients in
the ICU; (3) the intervention group received a PPI
(either parenteral or enteral), regardless of the dose, fre-
quency, or duration; (4) the control group received an
H2RA, either parenteral or enteral, regardless of the
dose, frequency, or duration; and (5) the outcomes in-
cluded all or any of the following: clinically important
GI bleeding; overt upper GI bleeding; pneumonia; mor-
tality, ICU length of stay, and/or Clostridium difficile
infection.
Search strategy
We updated our previous systematic review [12] and
searched MEDLINE, EMBASE, Cochrane Library, ACPJC,
and International Clinical Trial Registry Platform (ICTRP)
from March 2012 through November 2015. Our search
strategy is detailed in Additional file 1: Tables S3-S5.
We screened citations of all new potentially eligible
articles without language or publication date restrictions.
We conducted an electronic search of conference pro-
ceedings via a website provided by McMaster University
(http://library.mcmaster.ca/articles/proceedingsfirst). Two
reviewers (FA and EB) screened titles and abstracts to
identify articles for full review, and evaluated the full text
of potentially eligible studies. Disagreements between re-
viewers were resolved by consensus, and if necessary, con-
sultation with a third reviewer (WA).
Data extraction
Two reviewers (FA and EB) independently extracted per-
tinent data from all new studies utilizing a pre-designed
data abstraction form. Disagreements were resolved by
discussion and consensus. We contacted study authors
for missing or unclear information.
Risk of bias assessment
Two reviewers (FA and EB) independently examined
eligible trials for risk of bias using the Cochrane
Collaboration tool [27]. For each included trial, we
judged articles as having low, unclear, or high risk of
bias for the domains of adequate sequence generation,
allocation sequence concealment, blinding for object-
ive outcomes, incomplete outcome data, selective out-
come reporting, and for other bias. The overall risk
of bias for each trial included was categorized as low
if the risk of bias was low in all domains, unclear if
the risk of bias was unclear in at least one domain
and with no high risk of bias domain, or high if the
risk of bias was high in at least one domain. We re-
solved disagreements by discussion and consensus.
Statistical analysis
We analyzed data using RevMan software (Review
Manager, version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). We used the
DerSimonian and Laird [28] random-effects model to pool
the weighted effect of estimates across all studies. We esti-
mated study weights using the inverse variance method.
We calculated pooled relative risks (RRs) for dichotomous
outcomes and mean differences (MDs) for continuous
outcomes, with corresponding 95 % confidence intervals
(CIs). We assessed statistical heterogeneity using Chi2 and
I2 statistics [29]. We predefined substantial heterogeneity
as P < 0.10 or I2 > 50 %.
We calculated the number needed to treat (NNT) using
the method proposed by the Cochrane Collaboration [30].
We used an assumed control group (ACR) event rate of
3 % for clinically important bleeding and 5 % for overt GI
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bleeding; these ACRs were based on the results of a recent
observational study [7]. We inspected funnel plots
and performed Egger’s test to assess publication bias
[31]. We explored heterogeneity between studies by
performing predetermined subgroup analyses to inves-
tigate whether certain factors influenced the treatment
effect. These subgroups included high vs. low risk of
bias (hypothesizing that studies with high risk of bias
would have a larger treatment effect), PPI route of
administration (hypothesizing that the treatment effect
would be larger with parenteral administration), PPI
dose (hypothesizing that treatment effect would be
larger with higher dosing). In addition, we conducted
a post hoc sensitivity analysis, excluding trials pub-
lished in abstract form [20, 23, 32–35].
Results
Characteristics of studies included
Our new search identified a total of 255 citations. After
removing duplicates, 214 articles remained. Following
screening of titles and abstracts, 197 articles were ex-
cluded; 17 articles were retrieved for full text assessment
and 11 were excluded for variable reasons (Fig. 1). After
reviewing our previous results, we excluded an abstract
[36] (n = 202) that was later published as a full article
[35]. Another study was published as an abstract but
was excluded from the analysis because the necessary
data could not be obtained [37]. A total of six new trials
(n = 600 patients) are included in the different analyses.
Combining our previous and current results, 19 RCTs
[20, 22–25, 32–35, 38–48] from 20 reports (one study
Fig. 1 Process of identifying eligible studies: 18 trials (5 abstracts and 13 full published articles) were eligible and were included in the qualitative
and quantitative analyses. RCT randomized controlled trial
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published outcomes separately in two different reports)
[47, 48] met eligibility criteria and were included. Two
eligible trials were published in abstract form [32, 33];
further information was obtained after contacting the
authors.
Of 19 eligible trials [20, 22–25, 32–35, 38–48], 6 were
published as an abstract only [20, 23, 32–34, 38]
(Table 1). Overall, the included RCTs enrolled 2117
critically ill patients with a wide spectrum of medical
and surgical conditions. Ten trials used intravenous
PPIs, and eight used enteral PPIs, and the route was
not described in one trial, which was published in ab-
stract form. [23] The definitions for bleeding and
pneumonia varied across trials and are summarized in
Table 1.
Risk of bias assessment
Using the Cochrane risk of bias tool, three trials were
judged to be at low risk of bias, and for six trials the risk
of bias was unclear (Additional file 1: Table S6). We
could not evaluate the risk of bias in six trials published
as abstracts [20, 23, 32–34, 38]. In total, 10 trials were
judged to be at high risk of bias, primarily due to lack of
or inappropriate blinding.
Assessment of quality of the evidence
We used the GRADE method [26] to assess the quality
of evidence for individual outcomes. We present the de-
tails of our assessment in Table 2.
Main outcomes
A total of 14 trials enrolling 1679 patients reported
clinically important GI bleeding (Fig. 2). PPI use was
associated with lower risk of clinically important GI
bleeding compared to H2RAs (RR 0.39; 95 % CI 0.21,
0.71; P = 0.002; I2 = 0 %; moderate confidence). Using an
assumed control event rate of 3 %, the number needed
to treat (NNT) was 55 (95 % CI 42, 115). Seventeen tri-
als enrolling 1897 patients reported overt GI bleeding
(Fig. 3). Prophylaxis with PPI was associated with a
lower risk of overt GI bleeding compared to H2RA (RR
0.48; 95 % CI 0.34, 0.66; P < 0.0001; I2 = 3 %, moderate
confidence). The NNT to prevent GI bleeding was 37
(95 % CI 29, 59) for an assumed control event rate of
5 %. Thirteen trials enrolling 1571 patients reported the
risk of pneumonia (Fig. 4). The risk of pneumonia was
similar between groups (RR 1.12; 95 % CI 0.86, 1.46;
P = 0.39; I2 = 2 %, low confidence). Eleven trials enrol-
ling 1487 patients reported on mortality (Additional
file 1: Figure S5). Mortality risk was similar between
groups (RR 1.05; 95 % CI 0.87, 1.27; P = 0.61; I2 = 0 %,
moderate confidence). Seven trials enrolling 744 patients
reported ICU length of stay (Additional file 1: Figure S6);
ICU length of stay was not significantly different between
groups (MD –0.38 days; 95 % CI –1.49, 0.74; P = 0.51;
I2 = 30 %, low confidence). None of the RCTs included
reported on Clostridium difficile infection.
Subgroup analyses
We found no statistically significant interaction between
the magnitude of effect and risk of bias, route of PPI
administration, or frequency of PPI dosing. Details of
the results of the subgroup analyses are in Additional
file 1: Table S4 and S5.
Sensitivity analysis excluding trials published as ab-
stracts yielded results very similar to the primary ana-
lysis (RR 0.42; 95 % CI 0.21, 0.82; P = 0.01; I2 = 0 %)
(Additional file 1: Figure S7).
Publication bias
Visual inspection of the funnel plot for clinically import-
ant GI bleeding did not suggest the presence of publica-
tion bias (Additional file 1: Figure S8). The Egger test
also supported this conclusion (–0.69; 95 % CI –2.44,
0.84; P = 0.28). The Egger test was significant for overt
GI bleeding, which may suggest the presence of publica-
tion bias (–0.87; 95 % CI –1.67, –0.07; P = 0.03). We did
not find evidence of publication bias for the outcomes of
mortality and pneumonia (Additional file 1: Figure S9
and S10).
Discussion
This systematic review demonstrated moderate qual-
ity evidence that PPIs are superior to H2RAs in re-
ducing the risk of both clinically important and overt
GI bleeding. The relative treatment effect was large
(relative risk reduction of 61 % for clinically import-
ant GI bleeding), and the NNT was 55, which trans-
lates into 16 fewer bleeding events per 1000 patients.
The relatively low incidence of GI bleeding currently
seen in the ICU explains the apparent discrepancy
between a large relative effect and small absolute ef-
fect (Table 2).
The primary concern associated with PPI use in the
ICU is the potentially higher risk of infection, particu-
larly, pneumonia and C. difficile [19], potentially a con-
sequence of attenuation of the gastric acid protection
against bacteria. Patients with achlorhydria or on long-
term acid suppressive therapy have increased bacterial
growth on gastric mucosal biopsy [49]. Whether this
translates into increased risk of infection in critically ill
patients remains unknown.
Our meta-analysis did not suggest an increased risk of
pneumonia associated with PPIs rather than H2RAs.
Furthermore, mortality and duration of stay in the
ICU did not differ between groups. The impact of
acid suppressive therapy on Clostridium difficile infec-
tion is uncertain as none of the included trials reported on
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Table 1 Characteristics of trials included




MV patients with risk factors
Age (mean) 55.6 years
Male 59 %
APACHE II (mean) 23.7
Omeprazole 40 mg IV twice daily
loading, then 40 mg daily
(n = 178)
Cimetidine 300 mg IV bolus, then
infusion at 50 mg/h (n = 181)
(1) Bright red blood not clearing
after tube adjustment and lavage
(2) 8 h of persistent coffee grounds
material with aspirates every 2 h
not clearing with lavage or
(3) Persistent coffee grounds
material over 2–4 h on day 3–14 in






Critically ill patients with
risk factors
Age (mean) 56.7 years
Male 52 %
APAHE (mean) 55.3
Omeprazole 40 mg IV twice daily
(n = 38)
Ranitidine 150 mg/day IV (n = 38)
Sucralfate 1 g PO four times daily
(n = 32)





Age (mean) 64.5 years
Male 73 %
APACHE II NR
Rabeprazole 10 mg PO daily
(n = 70)
Ranitidine 300 mg PO daily
(n = 70)
Teprenone 150 mg NG daily
(n = 70)






Surgical ICU with risk factors
Age (mean) 47 years
Male 67 %
APACHE II (mean) 18.4
Omeprazole 40 mg IV daily
(n = 72)
Famotidine 40 mg IV twice daily
(n = 71)
Sucralfate 1 g PO four times daily
(n = 69)
Placebo (n = 75)
Overt bleeding with one of the
following:
(1) Drop in SBP >20 mmHg or rise
in HR >20 beats/min within 24 h
not explained by other causes or
(2) Drop in hemoglobin >2 g/dL
not explained by other causes
New or progressive infiltrate and 3
of the following:
(1) Purulent ETT aspirate with
>25 WBC/LPF
(2) Peripheral leukocytosis >11 × 109/
or >10 % bands
(3) Temperature >38.5 °C
(4) Pathogen from aspirate, BAL
(≥104 CFU/mL) or protected brush
sampling (≥103 CFU/mL)











Lansoprazole (tablet) NG (n = 23)
Ranitidine (n = 21) (dose and
frequency not reported)
Overt bleeding associated with





Medical and surgical ICU




Omeprazole 40 mg NG daily
(n = 32)
Ranitidine 50 mg IV bolus, then
150 mg IV daily (n = 35)
Overt bleeding with hemodynamic
instability, or a decrease Hb >2 g/dL










Rabeprazole 20 mg PO daily
(n = 20)
Famotidine 40 mg IV twice daily
(n = 10)










Table 1 Characteristics of trials included (Continued)
Phillips [32]
Abstract
USA (n = 58)




Omeprazole 40 mg PO, then
20 mg PO daily (n = 33)
Ranitidine 50 mg IV loading, then
150–200 mg/day infusion (n = 25)








Omeprazole 80 mg IV bolus, then
40 mg IV bolus three times daily
(n = 10)
Omeprazole 80 mg IV bolus then
40 mg IV infusion three times
daily (n = 10)
Ranitidine 50 mg IV three times
daily (n = 11) Placebo (n = 10)








Omeprazole 40 mg IV daily,
then 20 mg PO daily (n = 14)
Ranitidine 150 mg IV daily,
then 300 mg PO daily (n = 14)









Omeprazole 20 mg PO twice
daily (n = 61)
Ranitidine 50 mg IV twice daily
(n = 68)
Overt bleeding associated with one
of the following:
(1) 20 mmHg decrease in SBP or
DBP within 24 h or 20 beat/min
increase in HR or postural drop by
10 mmHg in SBP
(2) 2 g/dL decrease in Hb or 6 %
decrease in Hct within 24 h
(3) Lack of increase in Hb after two
units of packed cells
New infiltrate and two of the
following:
(1) Fever ≥38.3 °C
(2) WBC >10 × 109/L





Medical and surgical ICU




Pantoprazole 40 mg IV daily
(n = 32)
Pantoprazole 40 mg IV twice
daily (n = 38)
Pantoprazole 80 mg IV daily
(n = 23)
Pantoprazole 80 mg IV twice
daily (n = 39)
Pantoprazole 80 mg IV three
times daily (n = 35)
Cimetidine 300 mg IV bolus,
then 50 mg/h infusion (n = 35)
(1) Hematemesis or bright red
blood in gastric aspirate that did
not clear after tube adjustment
and 10-min lavage
(2) Persistent coffee ground
material for 8 h that did not clear
with lavage, or accompanied by
5 % decrease in Hct
(3) Decrease in Hct requiring ≥1
transfusions in the absence of
obvious source or










Pantoprazole 40 mg IV daily,
40 mg IV twice daily, 80 mg IV
daily, or 80 mg IV twice daily
(n = 158);
Cimetidine IV 300 mg bolus,
then 50 mg/h infusion (n = 31)



















Pantoprazole 40 mg IV daily
then 40 mg PO daily when
enteral feeds started (n = 60)
Ranitidine 50 mg IV three times
daily while NPO then 150 mg
PO daily when enteral feeds
started (n = 60)










Esomeprazole 40 mg PO daily
for 7 days (n = 30)
Famotidine 20 mg IV twice
daily for 7 days (n = 30)
Overt bleeding, or decreased
hemoglobin level >2 g/dL and
lesions on endoscopy
>48 h of ventilation and 3 or more of:
(1) Persistent (>48 h) or new infiltrate
(2) Positive sputum smear
(3) Fever >38.3 °C





Neurosurgical ICU with ICH
Age NA
Male 65 (58 %)
APACHE II NR
Omeprazole 40 mg IV twice
daily (n = 58)
Cimetidine 300 mg IV four times
daily (n = 54) Placebo (n = 53)
Overt bleeding that requires











PPI (n = 38) H2RA (n = 41)
No molecule, route, dose or
frequency described
No clear definition Leukocytosis, elevated procalcitonin,













Pantoprazole 40 mg IV daily
(n = 68)
Famotidine 20 mg IV twice
daily (n = 61)
Overt bleeding with any of the
following:
(1) Decrease in SBP by >20 mmHg
(2) Decrease in MAP to <65 mmHg
3. Decrease in Hb >2 g/dL and need








Omeprazole 40 mg PO daily
(n = 50)
Ranitidine 50 mg IV four times
daily (n = 50)
Sucralfate 1 gm PO four times
daily (n = 50)
NR NR NR
Description of populations, settings, interventions, outcomes and funding sources. APACHE Acute Physiology and Chronic Health Evaluation, MV mechanically ventilated, NR not reported, GI gastrointestinal, IV intravenous,
PO oral, hb hemoglobin, USFDA US Food and Drug Agency, SBP systolic blood pressure, HR heart rate, ETT endotracheal tube, WBC white blood cells, BAL, bronchiolar lavage, CFU colony-forming units, DBP diastolic blood










Table 2 Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) evidence profile
Quality assessment Patients, number Effect Quality
Studies,
number
Risk of bias Inconsistency Indirectness Imprecision Other considerations PPIs H2RAs Relative (95 % CI) Absolute (95 % CI)
Clinically important bleeding
14 Seriousa Not serious Not serious Not seriousb None 13/986 (1.3 %) 39/693 (5.6 %) RR 0.39 (0.21, 0.71) 15 fewer per 1000
(7–20 fewer)
Moderatea,b
Overt upper gastrointestinal bleeding




13 Seriousa Not seriousd Not serious Seriouse None 119/862 (13.8 %) 92/709 (13.0 %) RR 1.12 (0.86, 1.46) 16 more per 1000
(18 fewer to 60 more)
Lowa,d,e
Mortality
11 Not seriousf Not serious Not serious Seriouse None 151/874 (17.3 %) 120/614 (19.5 %) RR 1.05 (0.87, 1.27) 10 more per 1000
(25 fewer to 53 more)
Moderatee,f
ICU length of stay
7 Seriousg Not serious Not serious Serioush None 371 373 - MD 0.58 days fewer
(2.03 fewer to 0.86 more)
Lowg,h
The Guideline Development Tool was used to summarize the quality of evidence for individual outcomes based on five main domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias.
PPI proton pump inhibitor, H2RA histamine-2-receptor antagonist, MD mean difference, RR relative risk. aWe downgraded by one level, for risk of bias; most studies were unblinded. bAlthough the total number of
events was small, we did not downgrade for imprecision. cSignificant inconsistency was not present (I2 = 6 %). dSignificant inconsistency was not present (I2 = 4 %). eWe downgraded by one level for imprecision; the
confidence interval contains significant benefit and harm. fWe did not downgrade for risk of bias because mortality is an objective outcome that is less likely to be affected by lack of blinding in clinical trials. gWe










this. A systematic review of 12 observational studies
evaluating 2948 non-ICU patients with Clostridium
difficile found an association with acid suppressive
therapy (OR 1.94; 95 % CI 1.37, 2.75). This associ-
ation was larger with PPI use (OR 2.05; 95 % CI 1.47,
2.85) as compared to H2RA (OR 1.47; 95 % CI 1.06,
2.05), but the difference was not statistically signifi-
cant (P = 0.17) [50]. Furthermore, a retrospective co-
hort study that used propensity matching and
included over 30,000 critically ill patients suggested
that PPI use was associated with a small increase in
the risk of Clostridium difficile infection in compari-
son to H2RA (3.4 % vs. 2.7 %; P = 0.02) [19]. As these
results are limited by risk of bias associated with ob-
servational designs and imprecision, randomized trials
are needed to confirm or refute these observations.
Our meta-analysis used broad eligibility criteria to
enhance the generalizability of the results. Despite
including a wide spectrum of critically ill patients,
there was no significant heterogeneity across trials
for these outcomes. Our findings suggest that PPIs
are effective in preventing stress ulcer bleeding with-
out increasing the risk of pneumonia or mortality.
Nonetheless, several factors suggest cautious inter-
pretation of these results. The quality of evidence
was moderate for most outcomes; this is primarily
Fig. 2 Clinically important gastrointestinal bleeding. Data from 14 trials (n = 1679 patients) are included, analyzed using the random effects
model. Proton pump inhibitors (PPIs) were associated with a significantly lower risk of clinically important bleeding compared to histamine-2-
receptor antagonists (H2RAs). IV Inverse Variance
Fig. 3 Overt upper gastrointestinal bleeding. Data from 17 trials (n = 1897 patients) are included, analyzed using the random effects model.
Proton pump inhibitors (PPIs) were associated with a significantly lower risk of overt bleeding compared to histamine-2-receptor
antagonists (H2RAs). IV Inverse Variance
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related to risk of bias. Nine trials did not employ
proper blinding of healthcare providers or outcome
assessors (Additional file 1: Table S6), which may
have inflated the observed treatment effect of PPIs.
Furthermore, a subgroup analysis based on risk of
bias (low vs. high or unclear) suggested a larger
treatment effect in trials of lower quality, although
the test for interaction was not significant. The out-
come definitions varied across studies, which may
have affected the estimate of effect.
Other factors, such as enteral nutrition, may modify
the efficacy of prophylactic PPIs and H2RAs. One small
RCT in critically ill patients with burns showed that en-
teral nutrition increased gastric blood flow [51]. No
RCTs exclusively examined the effect of enteral feeding
on bleeding from stress ulcers. Whether enteral feeding
modifies the effect of PPIs on the risk of bleeding or
pneumonia remains uncertain.
Prior meta-analyses examined the effect of PPIs com-
pared to H2RAs for stress ulcer prophylaxis [11–14].
Our meta-analysis included more trials than other meta-
analyses on this topic (19 trials enrolling 2117 patients),
improving the precision of our findings. We obtained
additional missing data from the authors of the original
trial reports to inform the analyses, and conducted sub-
group analyses to assess the robustness of the findings.
Using the GRADE approach to assess our confidence in
the estimates of treatment effect, the certainty of evi-
dence was moderate for clinically important and overt
upper GI bleeding, and mortality outcomes, while it was
low for pneumonia and ICU length of stay outcomes.
We also adhered to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) report-
ing guidelines [52].
Conclusions
In summary, our meta-analysis provides moderate qual-
ity evidence for clinicians and guideline groups suggest-
ing that PPIs, when compared to H2RAs, lower the risk
of clinically important and overt GI bleeding among crit-
ically ill patients, without increasing the risk of pneumo-
nia and mortality, or ICU length of stay. The impact of
these drugs on the risk of Clostridium difficile infection
has yet to be examined in randomized trials in the ICU
setting.
Additional file
Additional file 1: Figure S5. Forest plot for ICU mortality. Data from
11 trials (n = 1487 patients) were included, analyzed using the random
effects model. The risk of death during the ICU stay was similar in both
groups. Figure S6. Forest plot for ICU length of stay. Data from 11 trials
(n = 744 patients) were included, analyzed using the random effects
model. The duration of ICU stay was similar in both groups. Figure S7.
Sensitivity analysis for clinically important bleeding, excluding trials
published as abstracts, shows similar results to the primary analysis.
Figure S8. Funnel plot for clinically important bleeding outcome. Visual
inspection does not show publication bias and the result for the Egger
test was –0.69 (95 % CI –2.44, 0.84; P = 0.28). Figure S9. Funnel plot for
pneumonia outcome. Visual inspection does not show publication bias.
Figure S10. Funnel plot for ICU mortality outcome. Visual inspection
does not show publication bias. (DOCX 1123 kb)
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